Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment

Table 1 Demographic and clinical features of patients

Demographic data	Value
Male/female	16/15
Caucasian/sub-Saharan/chinese1	22/8/1
Age (years: mean ± SD)	45.1 ± 10.2
Virological data
HBV-DNA positivity (persistent/fluctuant)2	28/3
HBV-DNA titters (IU/mL: Mean ± SD)3	1.4 × 103 ± 3.5 × 104
Clinical data4
Persistently normal/marginally altered AST or ALT	18/13
Persistently normal/marginally altered AST	25/6
Persistently normal/marginally altered ALT	20/11
AST (IU/L: mean ± SD)	25.6 ± 9.5
ALT (IU/L: mean ± SD)	28.5 ± 14.3
Fibrosis stage (Fibroscan)
F0-F1	22
F2	6
Not available	3

¹Origin country of sub-Saharan patients: 3 Equatorial Guinea, 2 Senegal, 1 Ivory Coast, 1 Ghana, and 1 Cameroon;

²Persistent/fluctuant: Positive results in more/less than the 90% of samples;

³In 16 samples from 8 patients, point flares of HBV-DNA titters (> 20000 IU/mL) were observed;

⁴Persistently normal/marginally altered: Normal values in more/less than the 90% of the samples. IU: International units; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; SD: Standard deviation.